Dr. Thomas Lechner joined ONO PHARMA USA, INC. in April 2022, assuming the role of Vice President, Medical Affairs, where he is responsible for establishing the company’s core medical strategy in the US. 

Thomas brings over 20 years of Medical Affairs experience in the U.S. and Europe and joined ONO PHARMA USA, INC to provide leadership and develop medical strategies for the U.S. Medical Affairs organization and late-stage pipeline compounds, respectively. In his prior experiences, Thomas held a variety of progressively responsible roles with Morphosys, Boehringer-Ingelheim, Pfizer Oncology, and the Health Care Consultancy Group in the U.S. and in Europe. 

Thomas has a Master of Science in Microbiology from the University of Innsbruck, Austria, and a Doctoral degree (Dr. rer. nat) in Molecular Genetics from the University of Innsbruck, Austria. Prior to moving to industry, he conducted his postdoctoral research in Epigenetics as a fellow at the Howard Hughes Medical Institute at Penn State University in the U.S.